Treatment of cancer of the head and neck

Shah, Jatin P.; Lydiatt, William M.

doi:10.3322/canjclin.45.6.352

Cited by 150 publications

(85 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In terms of treatment, there is a clear trend to incorporate new techniques and advances in treatment, particularly with the use of combined modality therapy, including surgery and radiotherapy or chemotherapy and radiation therapy. [3][4][5][6] However, the results regarding treatment should be interpreted with care, since changes in treatment also stem from individual and institutional biases influencing treatment selection.…”

Section: Discussionmentioning

confidence: 99%

“…For example, lip cancer has a 5-year survival rate over 80%, while hypopharynx cancer survival rates reach only about 30%. 4 It is also possible that the stage and site distribution of cancer cases has changed over time. Unfortunately, conventional methods of assessing head and neck cancer survival have sampled cancer cases in aggregate, thereby potentially obscuring changes in survival rates that have occurred over time in specific sites.…”

mentioning

confidence: 99%

“…4,6 Therefore, analysis of head and neck cancer as a group may obscure important differences in survival trends for site-specific tumors that are dependent upon site-specific treatment advances.…”

mentioning

confidence: 99%

“…However, during the last 2 decades many articles have consistently demonstrated advances in treatment, most notably the use of combination therapy (adjuvant radiotherapy after surgery, concurrent chemotherapy and radiotherapy) with improvements in survival rates. [3][4][5][6] In addition, improvements in radiotherapy and perioperative care, as well as prevention of chemotherapy-related complications, have resulted in increased quality of life and decreased treatment-related mortality. 6 Another important factor that may influence survival includes lead-time bias.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database

Carvalho¹,

Nishimoto²,

Califano³

et al. 2005

Intl Journal of Cancer

741

630

View full text Add to dashboard Cite

Despite recent advances in the diagnosis and treatment of head and neck cancer, there has been little evidence of improvement in 5-year survival rates over the last few decades. To determine more accurate trends in site-specific outcomes as opposed to a more general overview of head and neck cancer patients, we analyzed the site-specific data collected in the Surveillance, Epidemiology, Population-based cancer statistics in the United States (US) for 2004 is expected to yield 28,260 new cases of oral cavity and pharynx cancer and 20,260 new cases of larynx cancer, with a mortality of 7,230 and 3,830 deaths per year, respectively. 1 Despite improvements in diagnosis and treatment, in the last 3 decades there have been no changes in the 5-year survival rate for larynx cancer patients and only a slight but significant improvement for oral cavity and pharynx cancer patients when comparing patients treated during 1973-1977 (5-year survival rate of 53%) to patients treated during 1993-1997 (5-year survival rate of 56%) according to results based on data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. 2 This slight change in survival was first noted in the 2002 publication, 2 but these data can still be interpreted as indicating that "there is no change in prognosis for the last 2 decades" for head and neck cancer (HNC). However, during the last 2 decades many articles have consistently demonstrated advances in treatment, most notably the use of combination therapy (adjuvant radiotherapy after surgery, concurrent chemotherapy and radiotherapy) with improvements in survival rates. [3][4][5][6] In addition, improvements in radiotherapy and perioperative care, as well as prevention of chemotherapy-related complications, have resulted in increased quality of life and decreased treatment-related mortality. 6 Another important factor that may influence survival includes lead-time bias. New technologies such as fiberoptic laryngoscopy, more widespread dental professional screening for oral cancer and higher-resolution radiological techniques may result in earlier stage diagnosis for some tumors, as well as more accurate staging. 7-9 Such improvements in diagnosis may also occur in a site-specific manner.In addition, treatment for head and neck cancer has evolved and become site-specific with treatment modalities individualized for specific anatomic sites and stages. 4,6 Therefore, analysis of head and neck cancer as a group may obscure important differences in survival trends for site-specific tumors that are dependent upon site-specific treatment advances.For all historical periods, specific head and neck cancer sites have had very different treatment approaches and more importantly, different 5-year survival rates. For example, lip cancer has a 5-year survival rate over 80%, while hypopharynx cancer survival rates reach only about 30%. 4 It is also possible that the stage and site distribution of cancer cases has changed over time. Unfortunately, conventional methods of ...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database

Carvalho¹,

Nishimoto²,

Califano³

et al. 2005

Intl Journal of Cancer

741

630

View full text Add to dashboard Cite

show abstract

“…Это значительно снижает качество жизни больных. С другой стороны, завышение показаний к вы-полнению краевой или сегментарной резекции с целью предотвратить вышеуказанные нарушения может способ-ствовать увеличению частоты местных рецидивов из-за нарушения принципов онкологического радикализма [3].…”

unclassified

Experience in eliminating combined orofacial defects in the treatment of malignant neoplasms of the head and neck

Каприн¹,

Polyakov²,

Решетов³

et al. 2016

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

1 московский научно-исследовательский онкологический институт им. П.А. Герцена -филиал ФГБу «национальный медицинский исследовательский радиологический центр» (ген. директор -акад. рАн А.Д. каприн) минздрава россии, москва, россия; 2 ГБуЗ московской области «московский областной научно-исследовательский институт им. м.Ф. Владимирского», москва, россия Цель -устранение сложных комбинированных орофациальных дефектов после хирургического лечения больных со зло-качественными новообразованиями головы и шеи. Материал и методы. В мниои им П.А. Герцена с 1992 по 2015 г. вы-полнена реконструкция челюстно-лицевой зоны после радикального удаления злокачественных опухолей у 172 пациентов. Для устранения дефектов использовано 203 аутотрансплантата: висцеральных, кожно-мышечно-костных, кожно-мышеч-ных и кожно-фасциальных. В 29 случаях использовано 29 аутотрансплантатов. Представлены клинические наблюдения одномоментной одноэтапной реконструкции двумя микрохирургическими аутотрансплантатами и длительной многоэтап-ной реконструкции нижней зоны лица с применением двух аутотрансплантатов, отсроченного устранения дефекта сред-ней зоны лица химерным аутотрансплантатом. Результаты. Функциональная реабилитация осуществлена у 83% пациентов в общей группе больных. наименьший показатель реабилитации (69%) в группе больных с комбинированными дефектами нижней челюсти, полости рта, ротоглотки и мягких тканей. одномоментная одноэтапная реконструкция, в том числе с ис-пользованием нескольких аутотрансплантатов, обеспечивает лучшую анатомо-функциональную реабилитацию в кратчай-шие сроки после удаления опухоли и является предпочтительной для обеспечения качества жизни больного. Заключение. Выбор и количество трансплантатов зависят от тканевого состава, функциональной значимости восстанавливаемых тка-ней, сложности и размера дефекта. использование двух аутотрансплантатов для устранения сложных комбинированных дефектов является методом выбора и обеспечивает наилучший функциональный результат. Выполнение одномоментной реконструкции целесообразно у больных с невысоким риском рецидива опухоли при неинвазивной форме роста, с высо-кой дифференцировкой опухоли и может быть реализовано в стационарах с наличием подготовленных хирургов-онколо-гов в области лечения опухолей головы и шеи, реконструктивной микрохирургии, анестезиологов. Objective -to eliminate complex combined orofacial defects in patients with malignant neoplasms of the head and neck after surgical treatment. Subjects and methods. In 1992 to 2015, the P.A. Herzen moscow Oncology Research Institute reconstructed the maxillofacial region after radical removal of malignant tumors in 172 patients. 203 autografts including visceral, osteomyocutaneous, musculocutaneous, and fasciocutaneous ones were used to eliminate defects. 29 autografts were employed in 29 cases. The paper describes clinical cases of simultaneous one-stage lower face reconstruction using two microsurgical autografts, longterm multistep reconstruction with two autografts, and delayed elimination of midface defect with a chimer...

show abstract

Costs of Posttreatment Surveillance for Patients With Upper Aerodigestive Tract Cancer

Virgo¹,

Paniello²,

Johnson³

1998

Arch Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

Treatment of cancer of the head and neck

Cited by 150 publications

References 49 publications

Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database

Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database

Experience in eliminating combined orofacial defects in the treatment of malignant neoplasms of the head and neck

Costs of Posttreatment Surveillance for Patients With Upper Aerodigestive Tract Cancer

Contact Info

Product

Resources

About